This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
ç¨³å®šæ€§ç ”ç©¶ä¸€èˆ¬å…³æ³¨è„±é…°èƒºã€æ°§åŒ–与èšé›†ä¸‰ç±»é™è§£è·¯å¾„。脱酰胺多å‘生在天冬酰胺残基上，氧化常涉åŠç”²ç¡«æ°¨é…¸ä¸Žè‰²æ°¨é…¸ï¼Œèšé›†åˆ™ä¸Žæµ“度ã€æ¸©åº¦ä»¥åŠå®¹å™¨ç•Œé¢æŽ¥è§¦æœ‰å…³ã€‚强制é™è§£å®žéªŒç”¨äºŽè¯†åˆ«åˆ†åä¸è¾ƒæ•æ„Ÿçš„ä½ç‚¹ã€‚这些结果会直接影å“储å˜æ¡ä»¶çš„设定与有效期的判æ–。
冻干粉通常在低温环境下ä¿å˜ï¼Œå¤æº¶ä¹‹åŽéœ€è¦æŒ‰æŒ‡å®šæ¡ä»¶åœ¨è¾ƒçŸæ—¶é—´å†…使用。åå¤å†»èžå’Œå‰§çƒˆæŒ¯è¡å¯èƒ½ä¿ƒè¿›èšé›†ï¼Œä½Žå¸é™„容器则能å‡å°‘多肽在管å£ä¸Šçš„æŸå¤±ã€‚批å·ã€æ—¥æœŸä¸Žå¤„ç†æ¡ä»¶çš„完整记录，是åŽç»å¤æ ¸ä¸Žé—®é¢˜è¿½æº¯çš„基础。
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| 长期储å˜æ¸©åº¦ | 约 -20°C 或更低 | 冻干粉常è§ä¿å˜æ¡ä»¶ |
| å¤æº¶æº¶å‰‚ | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器æè´¨ | 低å¸é™„èšä¸™çƒ¯ | å‡å°‘多肽在管å£çš„å¸é™„æŸå¤± |
| 主è¦é™è§£è·¯å¾„ | 脱酰胺ã€æ°§åŒ–ã€èšé›† | ç”±åºåˆ—与工艺æ¡ä»¶å…±åŒå†³å®š |
| 追溯ææ–™ | 分æžè¯ä¹¦ä¸Žæ‰¹æ¬¡è®°å½• | 用于æ¥æºä¸Žçº¯åº¦æ ¸å®ž |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
The biosynthetic pathway of nicotine involves a coupling reaction between the two cyclic structures that comprise nicotine. Metabolic studies show that the pyridine ring of nicotine is derived from nicotinic acid, while the pyrrolidine is derived from N-methyl-Δ1-pyrrollidium cation. Biosynthesis of the two component structures proceeds via two independent syntheses, the NAD pathway for nicotinic acid and the tropane pathway for N-methyl-Δ1-pyrrollidium cation. The NAD pathway in the genus Nicotiana begins with the oxidation of aspartic acid into α-amino succinate by aspartate oxidase (AO). This is followed by a condensation with glyceraldehyde-3-phosphate and a cyclization catalyzed by quinolinate synthase (QS) to give quinolinic acid. Quinolinic acid then reacts with phosphoribosyl pyrophosphate catalyzed by quinolinic acid phosphoribosyl transferase (QPT) to form nicotinic acid mononucleotide (NaMN). The reaction now proceeds via the NAD salvage cycle to produce nicotinic acid via the conversion of nicotinamide by the enzyme nicotinamidase. The N-methyl-Δ1-pyrrollidium cation used in the synthesis of nicotine is an intermediate in the synthesis of tropane-derived alkaloids. Biosynthesis begins with decarboxylation of ornithine by ornithine decarboxylase (ODC) to produce putrescine. Putrescine is then converted into N-methyl putrescine via methylation by SAM catalyzed by putrescine N-methyltransferase (PMT).
=== Antibiotics === Empiric antibiotics are usually initiated as soon as the diagnosis of NSTI has been made. They are then changed to culture-guided antibiotic therapy. In the case of NSTIs, empiric antibiotics are broad-spectrum, covering gram-positive (including MRSA), gram-negative, and anaerobic bacteria. Often, a combination of clindamycin, daptomycin, IV vancomycin, and gentamicin is used. Gram-negative coverage may entail the use of fluoroquinolones, piperacillin/tazobactam, or carbapenems. Despite multiple studies, there is no consensus on how long antibiotics should be given. Generally, antibiotics are administered until surgeons decide that no further debridement is needed, and the patient no longer shows any systemic signs of infection from a clinical and laboratory standpoint. Evidence regarding the efficacy of treatment and adverse effects is also unclear.
This standard was written for a biological manufacturing company and was then written into the PDA's Technical Report # 39, thus establishing the industry standard for cold chain validation. This was critical for the industry due to the sensitivity of drug substances, biologics and vaccines to various temperature conditions. The FDA has also been very focused on this final area of distribution and the potential for a drug substances quality to be impacted by extreme temperature exposure. 4.6. Accuracy: Accuracy of an analytical procedure is the closeness of test results obtained by that procedure to the true value. The accuracy of an analytical procedure shall be established across its range. 4.7. Precision: The precision of an analytical procedure expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. 4.8. Method precision (Repeatability): Method precision carried out on different test preparation of a homogenous sample within short interval of time under same experimental conditions. 4.9. Intermediate precision (Ruggedness): Intermediate precision (Ruggedness) expresses within-laboratories variations i.e. different days, different analysts, different equipment etc. 4.10. Range: The range of an analytical procedure is the interval between the upper and lower concentration of analyte in the sample for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity
=== Operations in Russia === Dr. Reddy's Laboratories has faced significant criticism for its continued operations in Russia, despite the ongoing invasion of Ukraine and the imposition of international sanctions on the country. While many global pharmaceutical companies have ceased or drastically reduced their presence in Russia in response to the invasion, Dr. Reddy's has remained steadfast in maintaining its business there. In May 2022, the company reported a surge in sales, with revenues in Russia increasing by 70% year-over-year. The company's leadership declared that operations were continuing "as usual," and even announced plans to launch new products in the Russian market. This decision has sparked widespread ethical concerns, as Dr. Reddy's has been accused of prioritizing profits over the human suffering caused by the war. Despite the global condemnation of Russia's actions and the continued killings of civilians in Ukraine, Dr. Reddy's refusal to withdraw from Russia has raised questions about its commitment to international norms and human rights. The company has also faced backlash for its ties to the Russian Direct Investment Fund (RDIF), which has backed the Sputnik V vaccine, further complicating its position amid the conflict. By continuing operations in Russia, Dr. Reddy's is seen as contributing to the Russian economy and, by extension, supporting a regime responsible for war crimes and aggression.
== Diagnosis == Eclabium is very clearly visible and a medical professional can identify it easily. In some cases it can be diagnosed beforehand. For example, when there has been a surgery by the lip or gums, abnormal healing can be very likely. When the tissue does not heal properly it can result in the outward turning of the lip. Also, If a mother tests positive for a mutation in the ABCA12 gene, eclabium as a result of Ichthyosis can be present in the child. Ichthyosis is characterized by tight scaly skin along with ectropion which is outward turning of eyelids. If the skin is tight enough to be pulling on the eyes then it is safe to diagnose that the tight skin is also pulling on the lips making them turn outward If a patient is diagnosed with periodontitis it can cause swelling of the gums which in turn causes the outward turning of the lip.
Sources: en.wikipedia.org
==== United Arab Emirates ==== In October 2018, a Meat & Livestock Australia report said that while the United Arab Emirates's grocery retail sector is highly developed, traditional markets are still prominent throughout the country.
==== Human immunodeficiency virus type 1 (HIV) ==== The development of T cell-based AIDS vaccines using Sendai virus vectors is taking place reached phase II clinical trial. Evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus–vectored HIV type 1 gag vaccine demonstrated: induction of potent T-cell and antibody responses in prime-boost regimens.
=== Vasodilation and increased permeability === As defined, acute inflammation is an immunovascular response to inflammatory stimuli, which can include infection or trauma. This means acute inflammation can be broadly divided into a vascular phase that occurs first, followed by a cellular phase involving immune cells (more specifically myeloid granulocytes in the acute setting). The vascular component of acute inflammation involves the movement of plasma fluid, containing important proteins such as fibrin and immunoglobulins (antibodies), into inflamed tissue. Upon contact with PAMPs, tissue macrophages and mastocytes release vasoactive amines such as histamine and serotonin, as well as eicosanoids such as prostaglandin E2 and leukotriene B4 to remodel the local vasculature. Macrophages and endothelial cells release nitric oxide. These mediators vasodilate and permeabilize the blood vessels, which results in the net distribution of blood plasma from the vessel into the tissue space. The increased collection of fluid into the tissue causes it to swell (edema). This exuded tissue fluid contains various antimicrobial mediators from the plasma such as complement, lysozyme, antibodies, which can immediately deal damage to microbes, and opsonise the microbes in preparation for the cellular phase. If the inflammatory stimulus is a lacerating wound, exuded platelets, coagulants, plasmin and kinins can clot the wounded area using vitamin K-dependent mechanisms and provide haemostasis in the first instance.
=== Acquisition by Jollibee === Growing quickly, Smashburger was by 2013 considered an attractive prospect for an IPO. That year, it secured a $35 million debt facility from Golub Capital. This capital, in addition to the revenue generated by business operations, was thought to support two or three years worth of expansion by the chain. Its CEO said, though, that converting to a public company was a possibility for the company over the long-term. In 2015, Smashburger CEO Scott Crane again suggested the company could prepare for its own IPO at some point, saying it had until that point grown 20 to 25 percent and that it was adding 60 to 80 restaurants a year. In October 2015, the Philippine-based quick-service operator Jollibee Group announced that it had acquired a 40 percent stake in Smashburger for $100 million, in a deal that gave the chain an enterprise value of $335 million. Its CEO said the decision to sell would mean more stable long-term growth as opposed to relying on the stock market, which could be unpredictable. Following this, Smashburger began additional advertising, renegotiated leases for some of its restaurants and launched a subscription-based rewards program platform called Smash Pass in order to increase customer traffic. The chain also introduced Apple Pay, as well as offering specials like a pass that allows customers to buy a $1 burger a day for 54 days in a bid to build loyalty.
Sources: en.wikipedia.org
Approximately 9.4% of diabetes-related ER visits were for the uninsured. Women also have worse experiences with diabetes and care for diabetes than men do. Women experience more mental health issues, like eating disorders, associated with diabetes. Women are also three times more likely to be housebound because of societal pressures put on people with diabetes. Overall, women seek out more medical help, while at the same time receiving less help than men who are the same race and economic class. Transgender people also struggle with diabetes care reporting less preferential treatment than non-transgender people.
Estrogens are involved in libido (sex drive) in both women and men. In women, estrogen levels are elevated during the periovulatory period of the menstrual cycle, which is associated with increased sexual motivation. Libido is dependent on androgen levels only in the presence of estrogens. Without estrogens, free testosterone level actually decreases sexual desire. Sexual desire in women who have hypoactive sexual desire disorder can be restored by administration of estrogen (using oral contraceptive). Estrogens are required for female mammals to engage in lordosis behavior during estrus. This behavior is required for sexual receptivity in these mammals and is regulated by the ventromedial nucleus of the hypothalamus.
=== No development reported === AB-101 (RJ-101) – undefined mechanism of action – female sexual dysfunction [41] Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [42] Armodafinil ((R)-modafinil; D-modafinil; NH-02D; NH02D) – atypical dopamine reuptake inhibitor (DRI) – premature ejaculation [43] [44] Deuterated testosterone (d3-testosterone) – androgen (androgen receptor agonist) – female sexual dysfunction [45] Epelsiban (GSK557296; GSK-557296) – oxytocin receptor antagonist – premature ejaculation [46] Estradiol/testosterone topical gel (LibiGel-E/T; testosterone/estradiol topical gel) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [47] Fibroblast growth factor 1 (FGF-1; FGF1; Acidic FGF; aFGF; Cardio Vascu-Grow; CVBT-141P; CVBT-141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S) – fibroblast growth factor receptor (FGFR) agonist – erectile dysfunction [48] FKK-01PD (FKK-01PD; TGHW-01AP; TGHW01AP) – non-selective dopamine receptor agonist, other actions (apomorphine prodrug) – erectile dysfunction [49] GSK-958108 (GSK958108) – serotonin 5-HT1A receptor antagonist – premature ejaculation [50] HCP-1302 (HCP1302) – undefined mechanism of action – erectile dysfunction [51] Lidocaine topical gel – sodium channel blocker, local anesthetic – dyspareunia [52] PTL-2015 – undefined mechanism of action – erectile dysfunction [53] Research programme: nerve-targeted gene therapy - Periphagen (NC-3; NE-2; NE2-Endomorphin; NG-2; NG2-GAD; NN1-Neurotrophin) – various actions – erectile dysfunction [54] Research programme: sexual dysfunction therapy - Palatin Technologies (PL-6983) – melanocortin receptor modulators – erectile dysfunction, female sexual dysfunction [55] Sildenafil (KW-25084) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [56] Sildenafil orally soluble film (CURE-5003; CUREfilm Blue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [57] Sildenafil oral spray (Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; Sudamist) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [58] Tadalafil dry powder inhalation (Tadalafil Technosphere) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [59] Tadalafil orodispersible film tablet (Caliberi) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [60] Tadalafil topical (Extrinsa) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [61] Tadalafil/tamsulosin – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [62] Tunodafil (ecocarbamate; gluconocin; yonkenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [63] Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI), serotonin 5-HT1A receptor agonist – sexual function disorders [64] Zotarolimus (ABT-578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity; Resolute Onyx; ZoMaxx) – FK-binding protein 12 (FKBP12) ligand and mechanistic target of rapamycin (mTOR) inhibitor – erectile dysfunction [65]
Immunodeficiency, also known as immunocompromise, is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. Most cases are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection and environmental factors, such as nutrition. Immunocompromisation may also be due to genetic diseases/flaws such as SCID. In clinical settings, immunosuppression by some drugs, such as steroids, can either be an adverse effect or the intended purpose of the treatment. Examples of such use include organ transplant surgery as an anti-rejection measure and in patients with an overactive immune system, such as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency. A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised individual may be particularly vulnerable to opportunistic infections, in addition to normal infections that could affect anyone. It also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones. They are also more susceptible to infectious diseases owing to the reduced protection afforded by vaccines.
==== Feed additives ==== Enzymes are often added to animal feed to improve the health and growth of farmed animals, particularly chickens and pigs. The feed is typically treated with high pressure steam to kill bacteria such as Salmonella. Therefore the added enzymes (e.g. phytase and xylanase) must be able to withstand this thermal challenge without being irreversibly inactivated.
Sources: en.wikipedia.org
常用质谱测定分åé‡ï¼Œå†ç»“åˆè‚½å›¾æˆ–åºåˆ—分æžéªŒè¯ä¸€çº§ç»“构。å•ä¸€æ£€æµ‹æ‰‹æ®µä¸€èˆ¬éš¾ä»¥æŽ’除结构相近的类似物。多ç§æ–¹æ³•ç›¸äº’å°è¯æ›´ä¸ºå¯é 。
低温å¯ä»¥é™ä½Žæ°´è§£ä¸Žèšé›†çš„速率，从而延缓é™è§£è¿›ç¨‹ã€‚温度åå¤æ³¢åŠ¨æœ¬èº«ä¹Ÿå¯èƒ½é€ æˆç›¸å˜ä¸Žæ ·å“æŸå¤±ã€‚稳定的储å˜æ¡ä»¶æ˜¯å¯é‡å¤ç»“果的å‰æ。
分æžè¯ä¹¦ã€æ‰¹æ¬¡ç¼–å·ã€æ‰€ç”¨æ£€æµ‹æ–¹æ³•ä¸Žç»“果，以åŠæ ‡ç§°å‚¨å˜æ¡ä»¶ã€‚缺少方法细节的报告难以独立å¤æ ¸ã€‚记录完整性决定了追溯能å¦æˆç«‹ã€‚
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.